Background: The proportion of Mycoplasma pneumoniae isolates carrying point mutations in the 23S region of the genome associated with macrolide resistance has increased. We evaluated the probability of developing M. pneumoniae macrolide resistance mutations during macrolide treatment.
Methods: M. pneumoniae strains from initial and follow-up oropharyngeal samples from 38 Swedish patients were tested for 23S rRNA mutations by amplifying and pyrosequencing the gene target region. The duration of symptoms and of M. pneumoniae carriage were recorded in cases with and without the macrolide resistance mutation.
Results: Macrolide resistance mutations were absent in all baseline strains. Twenty-two patients were prescribed macrolides; the longest M. pneumoniae carriage time in these patients was 7 months and the longest symptomatic period was 7.5 months. Macrolide resistance was detected after macrolide treatment in 1 patient (carriage time 3.5 months and symptomatic period 7.5 months).
Conclusions: M. pneumoniae may develop macrolide resistance during macrolide treatment. A long duration of M. pneumoniae carriage and symptoms is common in patients regardless of the presence of resistance.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.3109/00365548.2013.866268 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Global prevalence, resistance rates, and underlying resistance mechanisms of clinical Mycoplasma and Ureaplasma species.
J Appl Microbiol
December 2024
Department of Dermatology, School of Medicine, University of Pretoria, South Africa.
Mycoplasmas are significant pathogens in human health, implicated in a range of clinical conditions from respiratory infections to urogenital disorders. Their resistance to commonly used antibiotics poses a substantial challenge to treatment and control. This study aims to provide a comprehensive overview of the global distribution of clinical mycoplasmas, elucidate their resistance to various antibiotics, and identify the genetic and molecular mechanisms underlying their resistance.
View Article and Find Full Text PDFAddition of macrolide antibiotics for hospital treatment of community-acquired pneumonia.
J Infect Dis
December 2024
The National Institute for Health Research Oxford Biomedical Research Centre, University of Oxford, Oxford, UK.
Background: Current guidelines recommend combining a macrolide with a β-lactam antibiotic for the empirical treatment of moderate-to-high severity community-acquired pneumonia (CAP); however macrolide use is associated with potential adverse events and antimicrobial resistance.
Methods: We analysed electronic health data from 8,872 adults in Oxfordshire, UK, hospitalised with CAP between 01-January-2016 and 19-March-2024, who received either amoxicillin or co-amoxiclav as initial treatment. We examined the effects of adjunctive macrolides on 30-day all-cause mortality, time to hospital discharge, and changes in Sequential Organ Failure Assessment (SOFA) score, using inverse probability treatment weighting to address confounding by baseline severity.
Occurrence, removal, and ecological risk of antibiotics and antibiotic resistance genes in township wastewater treatment plants in the upper reaches of the Yangtze River, China.
Environ Sci Pollut Res Int
December 2024
Nanjing University & Yancheng Academy of Environmental Protection Technology and Engineering, Yancheng, 224000, China.
The excessive use of antibiotics contributes significantly to environmental pollution and the widespread presence of antibiotic resistance genes (ARGs), which poses a serious threat to aquatic ecosystems and human health. Despite being a critical source of antibiotics and ARGs in the environment, research exploring their occurrence and removal characteristics in township wastewater treatment plants (WWTPs) remains limited. This study investigated the abundance and removal efficiencies of 39 antibiotics and 8 ARGs in influent and effluent samples from 40 township WWTPs located in the upper reaches of the Yangtze River.
View Article and Find Full Text PDFRetention of indoxyl sulfate in different genotypes of may explain variation in tacrolimus pharmacokinetics.
PeerJ
December 2024
Department of Pharmacy, Nanjing Drum Tower Hospital the Affiliated Hospital of Nanjing University Medical School, Nanjing, Jiangsu, China.
Background: Microbiota-derived toxins indoxyl sulfate and hippuric acid were previously reported to be associated with altered pharmacokinetics of the immunosuppressant tacrolimus in liver transplant recipients, and ABC transporter proteins are likely to be involved in the transport of such substances, but the role has not been elucidated. The aim of this study was to assess the retention of indoxyl sulfate and hippuric acid in the plasma of liver transplantation subjects carrying different genotypes of and (changes in transporter activity due to genetic variation), and to explore whether genetic variation is involved in altering the relationship between microbe-derived toxins and tacrolimus pharmacokinetics.
Methods: Liver transplantation subjects treated with the immunosuppressive regimen tacrolimus, corticosteroids, and mycophyolate mofetil were included and divided into normal renal function group and chronic kidney disease group.
Background: The effects of antibiotic use on children's gut microbiomes and resistomes are not well characterized in middle-income countries, where pediatric antibiotic consumption is exceptionally common. We characterized the effects of antibiotics commonly used by Peruvian children (i.e.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!